An experimental pill for idiopathic pulmonary fibrosis slowed lung function decline compared with placebo at the lower of two doses tested in a large phase 3 trial, Bristol Myers Squibb said Oct. 12. The 60 mg twice-daily dose of admilparant met the trial's main goal, but the 120 mg dose did not reach statistical significance, BioSpace reported. The company released only topline results with no effect sizes, so the size of the benefit is not yet known.
For people living with this scarring lung disease and their families, any new option draws attention. IPF has no cure, worsens over time, and is diagnosed most often in people 60 to 70 years old, according to the FDA. A split result like this one raises practical questions about whether the drug can reach patients and how strong its benefit will be.
